Johnson & Johnson

For my Corporate Public Relations class I was asked to chose a Fortune 100 company, create a blog and post about the company throughout the semester. I chose Johnson & Johnson because I am interested in crisis management and they are a great example of a company who has a great crisis management system. Last semester I learned a lot about the Tylenol crisis and how they dealt with it, which in the long run, enhanced their reputation.

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the health care field. They have more than 250 companies located in 57 countries around the world. The Company operates in three business segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Their Consumer segment provides people with a wide variety of everyday products including everything from hair care to caring for your allergies. Their Pharmaceutical segment discovers and develops prescription medicines for some of the world's most serious and prevalent diseases, ranging from cancer to HIV and AIDS. Their Medical Devices segment addresses some of the world's most chronic and pervasive conditions through the convergence of technologies, products and services.

The following talks briefly about the subsidiaries within Johnson& Johnson:
"In July 2009, Johnson & Johnson completed the acquisition of Cougar Biotechnology, Inc. with approximately 95.9% interest in Cougar Biotechnology's outstanding common stock. In September 2009, Elan Corporation, plc and Johnson & Johnson announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP). In March 2010, Hypermarcas SA acquired 99.99% of Versoix Participacoes Ltda from the Company. In September 2010, the Company acquired Micrus Endovascular, a global developer and manufacturer of minimally invasive devices for hemorrhagic and ischemic stroke (intrinsivest.com)."

Johnson & Johnson's current stock offering as of 2/21/11 is $61.11

Johnson & Johnson's share statistics:

Avg Vol (3 month)3:	10,775,700
Avg Vol (10 day)3:	8,924,900
Shares Outstanding5:	2.75B
Float:	2.75B
% Held by Insiders6:	0.04%
% Held by Institutions6:	64.50%
Shares Short (as of Jan 31, 2011)3:	25.65M
Short Ratio (as of Jan 31, 2011)3:	2.20
Short % of Float (as of Jan 31, 2011)3:	0.90%
Shares Short (prior month)3:	27.87M